OBI Pharma Inc (浩鼎生技) on Tuesday announced that its COVID-19 vaccine BCVax would enter phase 1 and 2 clinical trials in the second half of this year.
The results of animal experiments have shown that BCVax can produce high levels of antibody titers and has neutralizing effects against different variants of SARS-CoV-2, the company said.
While the company focuses primarily on cancer drugs, it has also been closely following currently available COVID-19 vaccines, OBI Pharma chairman Michael Chang (張念慈) said.
Photo: Chen Yung-chi, Taipei Times
Although the COVID-19 vaccine market seems to have turned into a “red ocean,” meaning cutthroat competition, OBI Pharma in July last year still proceeded with the research and development of a COVID-19 vaccine, Chang said.
The company has filed a provisional patent application with the US Patent and Trademark Office for its vaccine, and expects to submit applications for clinical trials with Taiwan’s Center for Drug Evaluation in July or August, he said.
A phase 1 clinical trial would take place in Taiwan in the second half of this year, while phase 2 trials would be conducted abroad, Chang said.
OBI Pharma would also seek partnerships to carry out phase 3 trials abroad involving more than 20,000 volunteers, Chang added.
The company said it initially planned to unveil its vaccine last month, but had to conduct animal tests focused on the Omicron variant of SARS-CoV-2 after the variant spread around the world late last year
BCVax is a recombinant protein-based vaccine, OBI lead scientific officer Lai Ming-tain (賴明添) said, adding that OBI Pharma wanted to create a vaccine with minimal side effects and effective adjuvants that can induce stronger T-cell responses.
Yang Ming-chen (楊明臻), who is a project manager at the company, said the vaccine works against different COVID-19 variants, including Omicron, thanks to immune stimulating complexes, which contain several copies of an antigen.
CHIP HANG-UP: Surging memorychip prices would deal a blow to smartphone sales this year, potentially hindering one of MediaTek’s biggest sources of revenue MediaTek Inc (聯發科), the world’s biggest smartphone chip designer, yesterday said its new artificial intelligence (AI) chips used in data centers are to account for 20 percent of its total revenue next year, as cloud service providers race to deploy AI infrastructure to meet voracious demand. MediaTek is believed to be developing tensor processing units for Google, which are used in AI applications. While it did not confirm such reports, MediaTek said its new application-specific IC (ASIC) business would be a new growth engine for the company. It again hiked its forecast for the addressable ASIC market to US$70 billion by 2028, compared
MediaTek Inc (聯發科), the world’s biggest smartphone chip supplier, yesterday said it plans to double investment in data center-related technologies, including advanced packaging and high-speed interconnect technologies, to broaden the new business’ customer and service portfolios. The chip designer is redirecting its resources to data centers, mainly designing application-specific integrated circuits (ASIC) with artificial intelligence (AI) capabilities for cloud service providers. The data center business is forecast to lead growth in the next three years and become the company’s second-biggest revenue source, replacing chips used in smart devices, MediaTek president Joe Chen (陳冠州) told a media event in Taipei. “Three or four years
Motorists ride past a mural along a street in Varanasi, India, yesterday.
Until US President Donald Trump’s return a year ago, when the EU talked about cutting economic dependency on foreign powers — it was understood to mean China, but now Brussels has US tech in its sights. As Trump ramps up his threats — from strong-arming Europe on trade to pushing to seize Greenland — concern has grown that the unpredictable leader could, should he so wish, plunge the bloc into digital darkness. Since Trump’s Greenland climbdown, top officials have stepped up warnings that the EU is dangerously exposed to geopolitical shocks and must work toward strategic independence — in defense, energy and
RSS